A Mab A Case Study In Bioprocess Development May 2026

A Mab reached the clinic in 28 months from transfection – 6 months ahead of schedule. Today, it’s a blockbuster therapy. But the bioprocess continues to evolve. The team is now implementing (perfused N-1 and connected capture) to boost productivity to 15 g/L and reduce COGS by 40%.

At 2L scale, everything worked. At 200L, A Mab showed unexpected (from 2% to 8%). The root cause: inhomogeneous mixing led to localized high pH (>7.8) near the base addition port. A Mab A Case Study In Bioprocess Development

Monoclonal antibodies (mAbs) have become the cornerstone of modern biopharmaceuticals, treating everything from oncology and autoimmune disorders to infectious diseases. However, the journey from a hybridoma cell line to a commercially viable product is fraught with complexity. For every successful mAb on the market, there are hundreds of failed attempts—not due to lack of efficacy, but often due to poor bioprocess development. A Mab reached the clinic in 28 months